Evolving Treatments for Advanced Renal Cell Carcinoma: ASCO 2023 and Beyond - Episode 13

Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

,

Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of First-Line Combination Therapy in Advanced Clear Cell RCC
    EP. 2: Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC
    EP. 3: Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
    EP. 4: Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC
    EP. 5: Selecting Therapy for a Real-World Patient With Clear Cell RCC
    EP. 6: Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
    EP. 7: Second-Line Treatment Armamentarium in Clear Cell RCC
    EP. 8: Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
    EP. 9: Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
    EP. 10: Renal Cell Carcinoma: Future Evolutions in Care
    EP. 11: Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)
    EP. 12: Available Treatment Options for Patients with Advanced RCC
    Now Viewing
    EP. 13: Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC
    EP. 14: Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC
    EP. 15: Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
    EP. 16: Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
    EP. 17: Future Perspectives in the Treatment of Advanced RCC
    x